Literature DB >> 19300881

What we have learned from the Myriad trials.

S B Hendrix1, G K Wilcock.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19300881     DOI: 10.1007/s12603-009-0044-7

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  7 in total

1.  Trials stopped early: too good to be true?

Authors:  S Pocock; I White
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

5.  A new clinical scale for the staging of dementia.

Authors:  C P Hughes; L Berg; W L Danziger; L A Coben; R L Martin
Journal:  Br J Psychiatry       Date:  1982-06       Impact factor: 9.319

6.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Authors:  Gordon K Wilcock; Sandra E Black; Suzanne B Hendrix; Kenton H Zavitz; Edward A Swabb; Mark A Laughlin
Journal:  Lancet Neurol       Date:  2008-04-29       Impact factor: 44.182

7.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112

  7 in total
  6 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  IAGG workshop: health promotion program on prevention of late onset dementia.

Authors:  S Andrieu; I Aboderin; J P Baeyens; J Beard; A Benetos; G Berrut; M Brainin; H B Cha; L K Chen; P Du; B Forette; F Forette; A Franco; L Fratiglioni; S Gillette-Guyonnet; G Gold; F Gomez; R Guimaraes; D Gustafson; A Khachaturian; J Luchsinger; F Mangialasche; H Mathiex-Fortunet; J P Michel; E Richard; L S Schneider; A Solomon; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

Review 4.  Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Authors:  R E Becker; N H Greig
Journal:  Curr Alzheimer Res       Date:  2010-11       Impact factor: 3.498

5.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

6.  Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.

Authors:  Guriqbal S Basi; Susanna Hemphill; Elizabeth F Brigham; Anna Liao; Danielle L Aubele; Jeanne Baker; Robin Barbour; Michael Bova; Xiao-Hua Chen; Michael S Dappen; Tovah Eichenbaum; Erich Goldbach; Jon Hawkinson; Rose Lawler-Herbold; Kang Hu; Terence Hui; Jacek J Jagodzinski; Pamela S Keim; Dora Kholodenko; Lee H Latimer; Mike Lee; Jennifer Marugg; Matthew N Mattson; Scott McCauley; James L Miller; Ruth Motter; Linda Mutter; Martin L Neitzel; Huifang Ni; Lan Nguyen; Kevin Quinn; Lany Ruslim; Christopher M Semko; Paul Shapiro; Jenifer Smith; Ferdie Soriano; Balazs Szoke; Kevin Tanaka; Pearl Tang; John A Tucker; Xiacong Michael Ye; Mei Yu; Jing Wu; Ying-Zi Xu; Albert W Garofalo; John Michael Sauer; Andrei W Konradi; Daniel Ness; George Shopp; Michael A Pleiss; Stephen B Freedman; Dale Schenk
Journal:  Alzheimers Res Ther       Date:  2010-12-29       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.